Role of choline PET/CT in guiding target volume delineation for irradiation of prostate cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue SUPPL. 1, 2013, Pages

  Schwarzenbock S M ^a   Kurth, J ^a   Gocke, Ch ^a   Kuhnt, T ^a   Hildebrandt, G ^a   Krause, B J ^a,b  

^a University Medical Centre Rostock   (Germany)

^b ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

Choline; Irradiation; PET CT; Prostate cancer; Target volume delineation

Indexed keywords

16BETA FLUORO 5ALPHA DIHYDROTESTOSTERONE F 18; ACETIC ACID C 11; CHOLINE C 11; CHOLINE F 18; FLUORINE 18; METHIONINE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CHOLINE; DIAGNOSTIC AGENT;

CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER TISSUE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; LYMPH NODE METASTASIS; LYMPHATIC DRAINAGE; PRIMARY TUMOR; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMIC THERAPY; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; IMAGE GUIDED RADIOTHERAPY; MALE; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; SCINTISCANNING; TUMOR RECURRENCE; PROSTATE TUMOR;

CHOLINE; HUMANS; LYMPHATIC METASTASIS; MALE; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOTHERAPY, IMAGE-GUIDED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84891614209     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2404-0     Document Type: Review

References (54)

1. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67-74.
2. Kupelian PA, Ciezki J, Reddy CA, Klein EA, Mahadevan A. Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;71(1):16-22.
3. De Meerleer G, Villeirs G, Bral S, Paelinck L, De Gersem W, Dekuyper P, et al. The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensitymodulated radiotherapy. Radiother Oncol. 2005;75(3):325-33.
4. Fonteyne V, Villeirs G, Speleers B, De Neve W, De Wagter C, Lumen N, et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys. 2008;72(3):799-807.
5. van Lin EN, Futterer JJ, Heijmink SW, van der Vight LP, Hoffmann AL, van Kollenburg P, et al. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CTwith dynamic contrast-enhanced and 1H-spectroscopicMRI. Int J Radiat Oncol Biol Phys. 2006;65(1):291-303.
6. Thorwarth D, Leibfarth S, Mönnich D. Potential role of PET/MRI in radiotherapy treatment planning. Clin Transl Imaging. 2013;1(1):45-51.
7. Picchio M, Giovannini E, Crivellaro C, Gianolli L, di Muzio N, Messa C. Clinical evidence on PET/CT for radiation therapy planning in prostate cancer. Radiother Oncol. 2010;96(3):347-50.
8. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-49.
9. Smith RA, Cokkinides V, Eyre HJ. Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects. CA Cancer J Clin. 2007;57(2):90-104.
10. Farsad M, Schwarzenbock S, Krause BJ. PET/CT and choline: diagnosis and staging. Q J Nucl Med Mol Imaging. 2012;56(4):343-53.
11. 11C-choline positron emission tomography. Eur Urol. 2002;42(1):18-23.
12. Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinschmidt K, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med. 2000;27(9):1415-9.
13. Kwee SA, Coel MN, Lim J, Ko JP. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol. 2005;173(1):252-5.
14. 18F-fluorocholine PET. J Nucl Med. 2006;47(2):262-9.
15. 11C-choline PET/CT. J Nucl Med. 2006;47(8):1249-54.
16. Schmid DT, John H, Zweifel R, Cservenyak T, Westera G, Goerres GW, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology. 2005;235(2):623-8.
17. Sutinen E,NurmiM, Roivainen A,VarpulaM, Tolvanen T, Lehikoinen P, et al. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging. 2004;31(3):317-24.
18. 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging. 2005;32(7):742-8.
19. Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med. 2005;46(10):1642-9.
20. Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C, et al. [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging. 2008;35(6):1065-73.
21. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol. 2006;176(3):954-60; discussion 60.
22. 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34(1):45-53.
23. Souvatzoglou M, Weirich G, Schwarzenboeck S, Maurer T, Schuster T, Bundschuh RA, et al. The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res. 2011;17(11):3751-9.
24. 18F-choline PET-CT detected simultaneous integrated boost. Radiother Oncol. 2009;93(2):213-9.
25. 18F-choline PET-CT to define a simultaneous integrated boost. Strahlenther Onkol. 2010;186(11):600-6.
26. 11C-choline PET/CT using multimodality fusion techniques. J Nucl Med. 2009;50(10):1585-93.
27. Ikonen S, Karkkainen P, Kivisaari L, Salo JO, Taari K, Vehmas T, et al. Magnetic resonance imaging of clinically localized prostatic cancer. J Urol. 1998;159(3):915-9.
28. Zakian KL, Sircar K, Hricak H, Chen HN, Shukla-Dave A, Eberhardt S, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology. 2005;234(3):804-14.
29. Pinkawa M, Piroth MD, Holy R, Klotz J, Djukic V, Corral NE, et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer - evaluation of quality of life with and without (18)F-choline PET-CT detected simultaneous integrated boost. Radiat Oncol. 2012;7:14.
30. Seppala J, Seppanen M, Arponen E, Lindholm P, Minn H. Carbon- 11 acetate PET/CT based dose escalated IMRT in prostate cancer. Radiother Oncol. 2009;93(2):234-40.
31. 11C-choline PET/CT of human prostate cancer using multimodality fusion techniques. Acad Radiol. 2010;17(5):614-23.
32. Chang JH, Joon DL, Lee ST, Gong SJ, Scott AM, Davis ID, et al. Histopathological correlation of (11)C-choline PET scans for target volume definition in radical prostate radiotherapy. Radiother Oncol. 2011;99(2):187-92.
33. 11C-choline positron emission tomography scans. Int J Radiat Oncol Biol Phys. 2012;83(5):e691-6.
34. Bundschuh RA, Wendl C, Weirich G, Souvatzoglou M, Treiber U, Geinitz H, et al. Tumour volume delineation in prostate cancer assessed by [(11)C]choline PET/CT: validation with surgical specimens. Eur J Nucl Med Mol Imaging. 2013. doi:10.1007/s00259-013-2345-7.
35. 18F-choline PET signal for target volume definition in radiation therapy of the prostate. Technol Cancer Res Treat. 2007;6(1):23-30.
36. Niyazi M, Bartenstein P, Belka C, Ganswindt U. Choline PET based dose-painting in prostate cancer - modelling of dose effects. Radiat Oncol. 2010;5:23.
37. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol. 2008;54(2):392-401.
38. Hacker A, Jeschke S, Leeb K, Prammer K, Ziegerhofer J, SegaW, et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol. 2006;176(5):2014-8; discussion 8-9.
39. Husarik DB, Miralbell R, DubsM, John H, Giger OT, Gelet A, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35(2):253-63.
40. 11C-Choline PET/CT in staging of primary prostate cancer: A histological correlation of PET/CT findings with respect to nodal metastatic disease. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2.
41. Krause BJ, Souvatzoglou M, Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol. 2011. doi:10.1016/j.urolonc.2010.08.008.
42. 11C-choline PET/ CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009;50(9):1394-400.
43. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35(1):18-23.
44. Rischke HC, Knippen S, Kirste S, Grosu AL. Treatment of recurrent prostate cancer following radical prostatectomy: the radiationoncologists point of view. Q J Nucl Med Mol Imaging. 2012;56(5):409-20.
45. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25(15):2035-41.
46. 11C-Choline PET/CT image-guided radiotherapeutic treatment of lymph nodal recurrence in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2008;35:288.
47. Souvatzoglou M, Krause BJ, Purschel A, Thamm R, Schuster T, Buck AK, et al. Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother Oncol. 2011;99(2):193-200.
48. Casamassima F, Masi L, Menichelli C, Bonucci I, Casamassima E, Lazzeri M, et al. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori. 2011;97(1):49-55.
49. Würschmidt F, Petersen C, Wahl A, Dahle J, Kretschmer M. [18F] fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol. 2011;6:44.
50. Geinitz H, Riegel MG, Thamm R, Astner ST, Lewerenz C, Zimmermann F, et al. Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy. Int J RadiatOncol Biol Phys. 2012;82(5):1930-7.
51. Swanson GP, Du F, Michalek JE, Hermans M. Long-term followup and risk of cancer death after radiation for post-prostatectomy rising prostate-specific antigen. Int J Radiat Oncol Biol Phys. 2011;80(1):62-8.
52. 11C-Choline PET/CT in lymph node restaging of patients with relapse of prostate cancer undergoing salvage lymphadenectomy: comparison with histopathology. Eur J Nucl Med Mol Imaging. 2010;37 Suppl 2.
53. Schwarzenböck S, Protzel C, Heuschkel M, Kurth J, Hakenberg OW, Krause BJ. Dual-phase F-18 choline PET/CT positive lymph nodes in patients with recurrent prostate cancer and salvage lymphadenectomy - correlation with histopathology. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 2.
54. 18F-fluorocholine PET-guided target volume delineation techniques for partial prostate re-irradiation in local recurrent prostate cancer. Radiother Oncol. 2009;93(2):220-5.